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Abstract
This article reviews the impact of human papilloma virus infection on the development of cervical cancer and the efficacy of newly 
developed HPV vaccines. These vaccines may have a major impact on the reduction of these common malignancies.
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(4):22-24
Introduction
The Human Papilloma Virus (HPV) is a non-enveloped double 
stranded DNA virus with more than 100 subtypes having been 
described. About 30–40 subtypes can infect the anogenital tract in men 
and women. These fall into two groups:  
(a) High-risk HPV types, of which HPV 16 and 18 and their relatives 
are the most important in causing anogenital cancer, of which by far 
the most important is cervical cancer 
(b) Low-risk types mainly HPV 6 and 11 which cause genital warts1
Even though HPV infection of the anogenital tract is very common, it 
appears that only once persistent infection has set in will the HPV lead 
to the development of premalignant conditions of the cervix, vulva, 
vagina, anus and in males, the penis. Fortunately persistent infection is 
not common and the overwhelming majority of infections, particularly in 
women < 35 years, will regress spontaneously and don’t persist.2
Epidemiology
HPV Infection is most common after the onset of sexual activity with 
a lifetime risk for sexually active men and women said to be at least 
50%, and probably closer to 80% by 50 years of age. It is estimated 
that about 630 million people globally will be infected annually but that 
in the overwhelming majority, the infection is transient and clears due 
to the cell-mediated immune response of the body. In the majority 
of cases, HPV infection produces no or minimal changes of clinical 
significance and people don’t even know they have the infection and 
as a result may spread it unknowingly. However, a small subset of 
patients will have persistent disease and develop pre-malignant lesions 
or invasive anogenital malignancies of which cervical cancer is the 
most important.3
HPV infection is most common in young patients. The five year 
cumulative risk of getting HPV infection in girls or young women 15–19 
years of age who are sexually active, is about 43%. This decreases to 
about 35% in women 20–24 years of age, to about 20% in women 25–
29 years of age and to about 24% in those of 30–44 years. In women > 
45 years there is still an appreciable risk of about 12%.4 
Discussion
HPV needs to invade actively dividing cells to survive. The superficial 
cells of the cervix have undergone differentiation and are no longer 
actively dividing. The cells within the cervix that are actively dividing are 
those within the basal layer. The HPV gains access to the basal layer 
via micro abrasions which commonly result from sexual intercourse. It 
can also gain access through naturally occurring accessible areas i.e. 
the transformational zone found in the cervix and anus. Although HPV 
infection is frequently transient, especially in young women, with about 
70–90% infections clearing within 24–36 months, persistent infection 
with high-risk types is strongly associated with the development of 
cervical intra-epithelial neoplasia (CIN) and cervical cancer. With 
integration of the virus into the replicative mechanisms of the basal 
cells, the impact of the E6 and E7 produced by the virus inhibits the 
P53 tumour suppressor encogene and the retinoblastoma gene 
respectively of the host cells. This results in desegregation of the 
chromosome during mitosis, chromosomal aberrations and impaired 
apoptosis which culminate over the years into cervical intra-epithelial 
neoplasia and finally invasive cervical cancer. Recently is has been 
reported that the risk of developing CIN or invasive cancer 10 years 
after the HPV infection is about 17% for HPV 16 and 13.5% for HPV 
18. Exposure and persistence are more frequent with HPV 16 than 
with the other HPV types.5
Cancer of the cervix in women is nevertheless a rare consequence 
of HPV infection with oncogenic HPV detected in over 99% of cases. 
Globally, it appears that HPV 16 is found in 50–60% of cases and HPV 
18 in 7-20% of cases worldwide. It is the second most common cancer 
in developing countries, based on age-standardised incidence rates. 
About 490 000 new cases of invasive cervical cancer are diagnosed 
annually on a global basis with about 80% occurring in the developing 
world. Unfortunately, as most of the patients will only be diagnosed 
when their disease is already advanced, about 275 000 will die 
annually. In Sub-Saharan Africa, cervical cancer is the most frequently 
diagnosed cancer and the leading cause of cancer mortality leading 
to about 55 000 women dying each year from this type of cancer. 
In South Africa each year about 7 000 women will develop cervical 
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cancer of which about 4 000 will die within the year. It is the most 
common cancer in South African black women accounting for about 
32% of all cancers in this group of women. The lifetime risk of cervical 
cancer amongst South African women is about 1 in 26. It is a disease 
that affects relatively young women and hence is an important cause 
of loss of years of life. From a global point of view it was estimated that 
cervical cancer caused the loss of 2.7 million years of life during 2000 
– the biggest single cause of loss of years of life from cancer in the 
developed world.6
High risk HPV infection is also associated with the development of 
other malignancies including oral, vulval, vaginal, penile and anal 
cancer and naturally the respective premalignant conditions of each 
of the above sites. Infection with low-risk types primarily HPV 6 and 
11 may lead to genital warts, and recurrent respiratory papillomatosis 
(RRP). Genital warts may be found on the vulva perineum, perianal 
area, vagina or cervix in women and on the penis or scrotum in men. 
Although they generally indicate benign cell proliferation, they may be 
a marker for exposure to high-risk groups of CIN. Genital warts rarely 
progress to malignancy, but commonly cause substantial physical and 
psychological morbidity because of their recurrence and resistance to 
treatment, particularly if larger. In young children, RRP is caused by 
vertical transmission of HPV infection and my lead to significant airway 
compromise. Repeated surgical procedures are often necessary.7, 8
In summary, but more specifically in line with the HPV vaccines that 
are now available i.e. the bivalent which has HPV types 16 and 18 in it 
and the quadrivalent, which has HPV types 6, 11, 16 and 18 in it, it is 
important to bear in mind that HPV types 6 and 11 account for about 
90% of genital warts in women and men and about 10% of low grade 
cervical lesions. HPV types 16 and 18 account for about 25% of low 
grade cervical lesions, 50% of high-grade cervical lesions, 70% of 
cervical cancers and about 70% of other genital cancers. Worldwide 
distribution of HPV types in cervical cancer support that high-risk HPV 
16 and 18 account for about 70% of cervical cancers, whilst HPV types 
31, 33, 35, 45, 52 and 58 account for a further 10%.9,10
Until the advent of the HPV vaccines, our primary strategy in combating 
cervical cancer has been through screening programmes. The aim 
of this secondary preventative measure is to identify premalignant 
conditions and then to subject these patients to conservative ablative 
or excisional strategies with the intention to decrease the likelihood of 
invasive disease and hence its accompanying morbidity and mortality.  
Screening for cervical cancer
The traditional method of screening has for years been cervical 
cytology. Although the South African Screening strategy has only 
had 1 pap smear every decade from about 25 years of age onwards 
for 3 decades as its cornerstone, it has proved very unsuccessful to 
counteract or decrease the incidence of invasive cancer or mortality 
related to the cancer. The developing world in general has had 
screening programmes that have been opportunistic, haphazard and 
particularly unsuccessful in combating cervical cancer. Liquid based 
cytology, HPV testing and visual assessment of the cervix after acetic 
acid or Lugol’s iodine application have all been proposed as possible 
options to overcome our present appalling state of affairs in screening 
for cervical cancer. Although a number of developed countries have 
managed to implement and maintain a screening protocol that has 
very successfully decreased incidence of invasive cervical cancer 
and mortality from the disease within their countries, it has required 
significant effort and input to establish and obtain resources, facilities, 
finances, education and political buy-in. In the overwhelming majority 
of developing countries where screening programmes are non-existent 
or have failed miserably, primary prevention utilising HPV vaccinations 
may be an option that merits serious attention.11 
Vaccines that prevent viral diseases such as polio, measles, smallpox 
and hepatitis B have provided some of the most successful strategies 
to reduce infectious disease associated morbidity and mortality. For 
example, prophylactic vaccination has reduced the incidence of 
infection by 72% for hepatitis B, 99,9% for measles, diphtheria and 
rubella and has almost completely eradicated polio and smallpox. 
The fact that cervical cancer is caused by high risk HPV, provides 
an exceptional opportunity to use vaccination as a tool for cancer 
prevention.12
The HPV vaccination has the potential to greatly reduce HPV 
associated disease and its accompanying burden worldwide which 
would include the pre-malignant lesions of the cervix, vulva and vagina 
and hence malignant lesions in the long-term as well as preventing 
condylomatous lesions of the lower anogenital tract.
Formulations of HPV vaccines
Prophylactic HPV vaccines are formulations of the major capsid 
proteins LI of the natural HPV particle. LI monomers in yeast, insects 
or mammalian cells self-assemble into virus like particles (VLPs) 
which closely mimic the structure of natural HPV virons. These VLPs 
are not toxic and don’t contain infectious genetic material. Because 
these VLPs are recombinant proteins, they are not oncogenic and 
don’t have disease producing potential. They are ideal for vaccination. 
Administration of these VLPs in the form of vaccinations produces 
neutralising antibodies that bind to natural HPV virons, preventing their 
entry into cells.13
The results of the first double-blind efficacy trial utilising HPV VLPs 
vaccines were published in 2002. This study randomly assigned 2 392 
women, aged 16–23 years, to receive 3 doses of vaccine or placebo, 
given at months 0, 2 and 6. Women were followed for a medium 
of 17 months after their 3rd dose. Of the 768 women who received 
the vaccine, none developed persistent infection (100% protective) 
compared with 41 cases in the 765 women in whom persistent 
infection was noted and who had received placebo. Furthermore, 
99.7% of all women vaccinated seroconverted with antibody levels 
between 50–100 fold higher than those produced in response to 
natural HPV 16 infection. The vaccine was shown to be safe and well 
tolerated.14
More recently two multivalent vaccines have been developed and 
used in a number of large studies. GlaxoSmithKline have produced 
the bivalent vaccine CERVARIX®, formulated to protect against HPV 
16 and 18, while Merck have developed the quadrivalent vaccine, 
GARDASIL®, to protect against HPV 6 and 11, 16, 18. Based on 
epidemiological data, an HPV 16 and 18 vaccine would be expected to 
prevent about 25% of all low grade SIL and about 50% of high grade 
SIL and about 70% invasive cancers. GARDASIL® would be expected 
to prevent an additional 12% of low grade SIL and nearly all cases of 
genital warts in line with it containing also HPV 6 and II VLPs.
In 2004, the results of CERVAVIX® vaccine trial were published. In the 
study more than 1 000 women, 15–25 years of age, were randomised 
to vaccine or placebo receiving their injections at months 0, 1 and 6, 
and followed for up to 27 months. Overall the vaccine was shown to be 
91.6% effective against incident infection and 100% against persistent 
infection. After a medium follow-up of 4.5 years, 98% of patients 
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vaccinated have maintained HPV 16 and 18 antibodies at about 
50–100 fold higher than that produced by natural HPV infection and 
have had 96.9%, 100% and 100% protection against incident infection, 
persistent infection and cervical intraepithelial lesions respectively. 15
The GARDASIL® vaccine has to date been evaluated in four placebo 
controlled, double blind, randomised phase II and phase III clinical 
studies involving over 20 500 women aged 16–26 years. These 
patients have been followed up for up to five years after enrollment. 
The vaccine prevented 100% of HPV 16 and 18 related CIN 2/3 and 
adenocarcinoma in situ of the cervix (AIS), 95% of HPV 6, 11, 16 and 
18 CIN 1, CIN 2/3 and AIS and 99% of genital warts caused by HPV 
6 and 11. It also prevented 100% of HPV 16 and 18 related vulval and 
vaginal pre-cancers (VIN 2/3 and VAIN 2/3) in women not previously 
exposed to the relevant HPV types. In addition, administration of the 
vaccine to women already with one or more vaccine related HPV types 
protected them from clinical disease caused by the remaining vaccine 
types. It did however, not obviously alter the cause of an infection 
that was already present. The vaccine was well tolerated and there 
were no vaccine related serious adverse events. When comparing 
HPV 6, 11, 16 and 18, immune responses in 9–15 year old girls with 
16–2 6year old females it was found that the immune responses were 
similar in both groups. Secondary analysis revealed that the vaccine 
was likely to have reduced cervical precancerous lesions and cervical 
cancer caused by HPV 16 and 18 by about 40% and of genital warts 
by about 70% in the four year follow-up. Most of the cases of the CIN 
and genital warts seen in those vaccinated resulted from infections that 
were present when the women received their vaccinations.16,17
Administration of HPV vaccine
For optimal effect, the vaccines should be given prior to sexual activity 
so that recipients will be naïve to all vaccine HPV types. The primary 
target are young girls aged 11–12 years, although it can be given to 
girls 9–10 years of age and to girls 13–26 years of age. Girls who are 
sexually active, should however still be given the vaccine, although 
they must be made aware that they will only obtain protection against 
those vaccine HPV types to which they have not been exposed. It is 
nevertheless most uncommon for any sexually active female to have 
been infected with all vaccine HPV types. Pre-vaccination cervical 
cytology of HPV testing is not necessary, although it is obligatory that 
following vaccination, all females must continue being screened for 
cervical cancer. A previous abnormal pap smear or a history of having 
a positive HPV test does not exclude that female from receiving the 
vaccination.  
The vaccines are administered intramuscularly and should ideally 
be given over 6 months, with CERVARIX® being given at 0, 1 and 
6 months, and GARDASIL at 0, 2 and 6 months. The vaccines are 
not recommended for use during pregnancy, even though there are 
no data to support that they are teratogenic. If pregnancy occurs 
during the course of administration, it is not necessary to terminate 
the pregnancy, although the injection must be immediately deferred 
and the course completed after the pregnancy. The vaccines can be 
administered during lactation. Simultaneous administration with other 
vaccines is not contraindicated and whilst they can be given to persons 
with minor acute illness, they should be deferred if persons have 
moderate or severe acute illnesses. The vaccines are prophylactic 
and don’t have any obvious therapeutic benefits i.e. they will not 
treat disease that is present. Adverse events appear to be mild and 
overwhelmingly confined to the site of injection, with pain, swelling or 
erythema being the most common. Pyrexia appears to occur in 1–4% 
and syncope in girls < 15 years have been described.
There is now also compelling data that both the vaccines will not only 
result in significantly elevated levels of antibodies to their vaccine HPV 
types, but also to significantly elevated antibody levels to types 31, 45 
predominantly, and 33, 35, 52, 58. This cross protection does not only 
extend to antibody levels, but also to clinical protection to development 
of incident and persistent infection and to cervical intraepithelial 
neoplasia caused by these HPV types.
Conclusion
The data pertaining to the role of HPV vaccines in eradicating cervical 
cancer are remarkable, inspiring and exciting. It is overwhelmingly 
clear that HPV vaccines are highly effective, highly immunogenic 
and very well tolerated. There is real hope that cervical cancer can 
be substantially reduced throughout the world and particularly so 
in the developing world. However, despite the remarkable efficacy 
of the vaccines there are unfortunately many questions that remain 
regarding its distribution and implementation. The biggest hurdle is 
likely to be cost. It is likely that the cost of the vaccine will be exorbitant 
from a South Africa perspective, even though there has been verbal 
assurance on the part of the pharmaceutical companies that a 
differential cost between the developed and developing world will exist. 
Be it through coercion, innovative planning or endless negotiations, 
finances must be earmarked for implementing this long awaited 
strategy in trying to eradicate cervical cancer in Southern Africa. 
Implementation will unfortunately be influenced by ethical, cultural, 
social and religious connotations.
Awareness programmes, enlightenment and education are going to 
be a priority in establishing meaningful vaccination programmes. It 
mandates cooperation and consideration of all role players, including 
paediatricians, gynaecologists, family medicine practitioners, nursing 
staff, members of the department of health and the pharmaceutical 
companies. I do believe that all these issues, including cost, can be 
resolved.  
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